Hhlr Advisors, Ltd. Biomarin Pharmaceutical Inc Transaction History

Hhlr Advisors, Ltd.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $9.77 Million - $10.9 Million	-114,900 Reduced 50.19%	114,042 $10.1 Million
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $6.91 Million - $8 Million	-79,751 Reduced 25.84%	228,942 $19.8 Million
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $27.1 Million - $36.2 Million	308,693 New	308,693 $30 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

Stay updated on Hhlr Advisors, Ltd. with notifications on news.